Robert W. Mahley

Q: What Schools Are Affiliated With Robert W. Mahley

Robert W. Mahley is affiliated with the following schools: Washington University in St. Louis, University of California, San Francisco, University of Cambridge

Robert W. Mahley's AcademicInfluence.com Rankings

Robert W. Mahley

Biology

#3132

World Rank

#4832

Historical Rank

Neuroscience

#276

World Rank

#291

Historical Rank

biology Degrees

Download Badge

Biology

Robert W. Mahley's Degrees

Masters Medicine University of California, San Francisco
PhD Biochemistry University of California, San Francisco

Why Is Robert W. Mahley Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert W. Mahley's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. (1988) (3954)
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk (2010) (2087)
Apolipoprotein E: far more than a lipid transport protein. (2000) (1609)
Ancient human genomes suggest three ancestral populations for present-day Europeans (2013) (1082)
Plasma lipoproteins: apolipoprotein structure and function. (1984) (1012)
The Simons Genome Diversity Project: 300 genomes from 142 diverse populations (2016) (1009)
Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. (2006) (900)
Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. (1994) (816)
Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. (1985) (741)
Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. (1981) (689)
Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. (1999) (688)
Lipoprotein receptors and cholesterol homeostasis. (1983) (683)
Human apolipoprotein E. The complete amino acid sequence. (1982) (665)
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. (1987) (663)
Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. (1982) (657)
Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. (1991) (615)
Meta-analysis and imputation refines the association of 15q25 with smoking quantity (2010) (605)
Expression of apolipoprotein E during nerve degeneration and regeneration. (1986) (555)
Complete protein sequence and identification of structural domains of human apolipoprotein B (1986) (549)
Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. (1978) (514)
A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. (1989) (508)
Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. (1985) (469)
Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. (1987) (454)
Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. (1990) (448)
A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. (1980) (447)
Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases (2014) (428)
Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease (2010) (417)
Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. (1994) (412)
Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus (2006) (403)
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. (1982) (400)
Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. (1999) (395)
Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. (1990) (391)
Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. (1999) (391)
Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. (1978) (379)
Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons (2001) (361)
Expression of Human Apolipoprotein E3 or E4 in the Brains ofApoe−/− Mice: Isoform-Specific Effects on Neurodegeneration (1999) (358)
Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice (2004) (355)
LDL-cholesterol concentrations: a genome-wide association study (2008) (355)
Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. (1995) (353)
Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. (1998) (352)
Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. (1980) (349)
Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor. Identity with the chylomicron remnant transport process. (1980) (344)
Human apolipoprotein E: the Alzheimer's disease connection (1996) (332)
Two independent lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo-B,E and apo-E receptors. (1981) (329)
Stable Expression and Secretion of Apolipoproteins E3 and E4 in Mouse Neuroblastoma Cells Produces Differential Effects on Neurite Outgrowth (*) (1995) (327)
Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice (2003) (315)
Lipoprotein binding to canine hepatic membranes. Metabolically distinct apo-E and apo-B,E receptors. (1981) (314)
Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. (1977) (309)
Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. (1982) (308)
Apolipoprotein E Sets the Stage: Response to Injury Triggers Neuropathology (2012) (308)
Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders (2016) (307)
Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. (1995) (305)
Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. (1994) (296)
Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. (1993) (290)
Alterations of the plasma lipoproteins and apoproteins following cholesterol feeding in the rat. (1977) (289)
Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. (2005) (288)
Subfractionation of human high density lipoproteins by heparin-Sepharose affinity chromatography. (1980) (287)
Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. (1995) (284)
Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoproteins. (1979) (284)
Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. (1981) (282)
Atherogenic hyperlipoproteinemia. The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. (1982) (277)
Cholesteryl ester synthesis in macrophages: stimulation by beta-very low density lipoproteins from cholesterol-fed animals of several species. (1980) (264)
Nucleotide sequence and structure of the human apolipoprotein E gene. (1985) (262)
Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. (1979) (250)
Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. (2005) (249)
The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. (1983) (245)
Swine lipoproteins and atherosclerosis. Changes in the plasma lipoproteins and apoproteins induced by cholesterol feeding. (1975) (242)
GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. (2009) (234)
Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. (1994) (232)
Canine lipoproteins and atherosclerosis. II. Characterization of the plasma lipoproteins associated with atherogenic and nonatherogenic hyperlipidemia. (1974) (231)
Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. (1986) (220)
Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. (1990) (217)
Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. (1994) (213)
Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. (1992) (211)
Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans. (1994) (207)
Lipoprotein uptake by neuronal growth cones in vitro. (1987) (203)
The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. (1983) (202)
Overexpression and Accumulation of Apolipoprotein E as a Cause of Hypertriglyceridemia* (1998) (199)
Uptake of chemically modified low density lipoproteins in vivo is mediated by specific endothelial cells (1985) (194)
Verapamil suppresses atherosclerosis in cholesterol-fed rabbits. (1983) (192)
Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism. (2016) (189)
Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. (1991) (185)
Canine Lipoproteins and Atherosclerosis: I. Isolation and Characterization of Plasma Lipoproteins from Control Dogs (1974) (184)
A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. (1980) (183)
Putting cholesterol in its place: apoE and reverse cholesterol transport. (2006) (179)
Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. (1988) (177)
Apoprotein (E--A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. (1978) (175)
Rate and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) and low density lipoproteins to human fibroblasts: evidence for multiple receptor binding of apo-E HDLc. (1979) (169)
Lipoprotein-receptor interactions. (1986) (168)
A Genome-Wide Association Study Reveals Variants in ARL15 that Influence Adiponectin Levels (2009) (164)
Apolipoprotein E4 Potentiates Amyloid β Peptide-induced Lysosomal Leakage and Apoptosis in Neuronal Cells* (2002) (161)
ALTERATIONS IN HUMAN HIGH-DENSITY LIPOPROTEINS, WITH OR WITHOUT INCREASED PLASMA-CHOLESTEROL, INDUCED BY DIETS HIGH IN CHOLESTEROL (1978) (160)
Heparan Sulfate Proteoglycans Participate in Hepatic Lipaseand Apolipoprotein E-mediated Binding and Uptake of Plasma Lipoproteins, Including High Density Lipoproteins* (1997) (158)
Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE ε4/ε4 genotype accelerates HIV disease progression (2008) (158)
Obligatory role of cholesterol and apolipoprotein E in the formation of large cholesterol-enriched and receptor-active high density lipoproteins. (1985) (154)
Apolipoprotein E4 Domain Interaction Mediates Detrimental Effects on Mitochondria and Is a Potential Therapeutic Target for Alzheimer Disease* (2010) (153)
Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. (2007) (152)
Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. (1984) (152)
Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. (1979) (144)
Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. (1983) (144)
ISOLATION OF A GOLGI APPARATUS-RICH FRACTION FROM RAT LIVER (1970) (144)
Structural and metabolic heterogeneity of beta-very low density lipoproteins from cholesterol-fed dogs and from humans with type III hyperlipoproteinemia. (1982) (141)
Genome‐wide Linkage and Association Analyses to Identify Genes Influencing Adiponectin Levels: The GEMS Stud (2009) (139)
Cell surface receptor binding of phospholipid . protein complexes containing different ratios of receptor-active and -inactive E apoprotein. (1980) (139)
Enhanced binding and uptake of remnant lipoproteins by hepatic lipase-secreting hepatoma cells in culture. (1994) (137)
Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia. (1984) (134)
Differential Cellular Accumulation/Retention of Apolipoprotein E Mediated by Cell Surface Heparan Sulfate Proteoglycans (1998) (132)
Increased tau Phosphorylation in Apolipoprotein E4 Transgenic Mice Is Associated with Activation of Extracellular Signal-regulated Kinase (2004) (131)
Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. (1994) (131)
Canine hyperlipoproteinemia and atherosclerosis. Accumulation of lipid by aortic medial cells in vivo and in vitro. (1977) (131)
Alzheimer's disease: Apolipoprotein E and cognitive performance (2000) (130)
Formation of cholesterol- and apoprotein E-enriched high density lipoproteins in vitro. (1983) (129)
DNA sequence of the human apolipoprotein B gene. (1987) (126)
Immunoregulatory plasma lipoproteins. Role of apoprotein E and apoprotein B. (1980) (125)
Foam Cells in Explants of Atherosclerotic Rabbit Aortas Have Receptors for β‐Very Low Density Low Density Lipoproteins and Modified Low Density Lipoproteins (1983) (124)
Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein [a] and that cause lipid accumulation in macrophages. (1986) (124)
[13] Isolation and characterization of apolipoprotein E (1986) (123)
Interaction of swine lipoproteins with the low density lipoprotein receptor in human fibroblasts. (1976) (122)
Astroglial Regulation of Apolipoprotein E Expression in Neuronal Cells (2004) (122)
Lactoferrin binding to heparan sulfate proteoglycans and the LDL receptor-related protein. Further evidence supporting the importance of direct binding of remnant lipoproteins to HSPG. (1994) (117)
Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. (1995) (117)
Overexpression of Hepatic Lipase in Transgenic Mice Decreases Apolipoprotein B-containing and High Density Lipoproteins (1998) (117)
Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing of a new variant. (1984) (117)
Chylomicron and chylomicron remnant catabolism (1991) (115)
Reactivity of apolipoprotein E4 and amyloid beta peptide: lysosomal stability and neurodegeneration. (2006) (115)
Characterization of lipoprotein particles isolated from the Golgi apparatus of rat liver. (1969) (114)
Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons* (2011) (114)
Genes contributing to prion pathogenesis. (2008) (114)
Chylomicron-chylomicron remnant clearance by liver and bone marrow in rabbits. Factors that modify tissue-specific uptake. (1989) (111)
Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E. (1984) (111)
Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease) (2007) (110)
Regulation of hepatic lipoprotein receptors in the dog. Rapid regulation of apolipoprotein B,E receptors, but not of apolipoprotein E receptors, by intestinal lipoproteins and bile acids. (1983) (110)
Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. (1983) (110)
Binding of chylomicron remnants and beta-very low density lipoproteins to hepatic and extrahepatic lipoprotein receptors. A process independent of apolipoprotein B48. (1984) (109)
Isolation and characterization of an apoprotein from the d<1.006 lipoproteins of human and canine lymph homologous with the rat A-IV apoprotein (1978) (109)
Apoprotein (E--A-II) complex of human plasma lipoproteins. II. Receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E--A-II) complex. (1978) (105)
Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. (1989) (105)
Interaction of canine and swine lipoproteins with the low density lipoprotein receptor of fibroblasts as correlated with heparin/manganese precipitability. (1977) (103)
Inhibition of receptor-mediated clearance of lysine and arginine-modified lipoproteins from the plasma of rats and monkeys. (1980) (102)
Chylomicron metabolism. Chylomicron uptake by bone marrow in different animal species. (1989) (102)
The rat arginine-rich apoprotein and its redistribution following injection of iodinated lipoproteins into normal and hypercholesterolemic rats. (1977) (101)
A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1. (1984) (100)
Uptake of cholesterol-rich remnant lipoproteins by human monocyte-derived macrophages is mediated by low density lipoprotein receptors. (1988) (99)
Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant. (1989) (98)
Lipoproteins associated with the Golgi apparatus isolated from epithelial cells of rat small intestine. (1971) (97)
Type III hyperlipoproteinemia: recent insights into the genetic defect of familial dysbetalipoproteinemia. (1984) (96)
Yucatan miniature swine as a model for diet-induced atherosclerosis. (1982) (96)
Apolipoprotein E (2007) (95)
Disparities in the interaction of rat and human lipoproteins with cultured rat fibroblasts and smooth muscle cells. Requirements for homology for receptor binding activity. (1980) (95)
Atherogenic lipoproteins and coronary artery disease: concepts derived from recent advances in cellular and molecular biology. (1985) (93)
Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology. (2012) (93)
Epidemiology of hepatitis E virus infection in Turkey (1993) (91)
Elevated hepatic lipase activity and low levels of high density lipoprotein in a normotriglyceridemic, nonobese Turkish population. (1999) (91)
Topographic Study of Sudanophilic Lesions in Cholesterol‐Fed Minipigs by Image Analysis (1985) (89)
Atherogenic hyperlipoproteinemia induced by cholesterol feeding the Patas monkey. (1976) (88)
Abnormal lecithin:cholesterol acyltransferase activation by a human apolipoprotein A-I variant in which a single lysine residue is deleted. (1984) (88)
Structure-dependent Impairment of Intracellular Apolipoprotein E4 Trafficking and Its Detrimental Effects Are Rescued by Small-molecule Structure Correctors* (2011) (86)
Low levels of high density lipoproteins in Turks, a population with elevated hepatic lipase. High density lipoprotein characterization and gender-specific effects of apolipoprotein e genotype. (2000) (86)
Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma. (1998) (86)
Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology (2006) (86)
Complete cDNA and derived protein sequence of human apolipoprotein B-100. (1986) (86)
Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis. (1999) (86)
Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease (2000) (86)
Identification of apolipoprotein B-100 low density lipoproteins, apolipoprotein B-48 remnants, and apolipoprotein E-rich high density lipoproteins in the mouse. (1994) (85)
Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia. (1983) (84)
Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. (1994) (84)
Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons (2008) (83)
Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). (2005) (81)
Apolipoprotein E2 Reduces the Low Density Lipoprotein Level in Transgenic Mice by Impairing Lipoprotein Lipase-mediated Lipolysis of Triglyceride-rich Lipoproteins* (1998) (79)
Apolipoprotein E Is the Determinant that Mediates the Receptor Uptake of B‐Very Low Density Lipoproteins by Mouse Macrophages (1986) (79)
Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism. (1991) (79)
Mapping of Human Apolipoprotein B Antigenic Determinants (1987) (77)
Familial defective apolipoprotein B-100: enhanced binding of monoclonal antibody MB47 to abnormal low density lipoproteins. (1988) (77)
Endogenous apolipoprotein E modulates cholesterol efflux and cholesteryl ester hydrolysis mediated by high-density lipoprotein-3 and lipid-free apolipoproteins in mouse peritoneal macrophages (2000) (75)
Isolation and characterization of the apolipoprotein E receptor from canine and human liver. (1986) (75)
Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. (1998) (75)
An electrophoretic method for the quantitative isolation of human and swine plasma lipoproteins. (1974) (74)
Development of accelerated atherosclerosis. Concepts derived from cell biology and animal model studies. (1983) (72)
Human apolipoprotein E. Receptor binding activity of truncated variants with carboxyl-terminal deletions. (1989) (72)
Apolipoprotein E4 Domain Interaction Occurs in Living Neuronal Cells as Determined by Fluorescence Resonance Energy Transfer* (2004) (71)
Role of Heparan Sulfate Proteoglycans and the LDL Receptor‐Related Protein in Remnant Lipoprotein Metabolism a (1994) (68)
Identity of Very Low Density Lipoprotein Apoproteins of Plasma and Liver Golgi Apparatus (1970) (67)
Central Nervous System LipoproteinsHighlights (2016) (67)
Lipoproteins, neurobiology, and Alzheimer's disease: structure and function of apolipoprotein E (1994) (65)
Modulating Effects of Canine High Density Lipoproteins on Cholesteryl Ester Synthesis Induced by B‐Very Low Density Lipoproteins in Macrophages: Possible In Vitro Correlates with Atherosclerosis (1982) (65)
Cellular and Molecular Biology of Lipoprotein Metabolism in Atherosclerosis (1981) (65)
Apolipoprotein E‐binding Proteins Isolated from Dog and Human Liver (1988) (64)
Chylomicron metabolism during dietary-induced hypercholesterolemia in dogs. (1981) (63)
Receptor binding of cholesterol-induced high-density lipoproteins containing predominantly apoprotein E to cultured fibroblasts with mutations at the low-density lipoprotein receptor locus. (1980) (61)
Common polymorphisms of ATP binding cassette transporter A1, including a functional promoter polymorphism, associated with plasma high density lipoprotein cholesterol levels in Turks. (2005) (59)
Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit (2012) (58)
DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women (2002) (58)
Chylomicron remnant metabolism. Role of hepatic lipoprotein receptors in mediating uptake. (1989) (57)
Lipoproteins of Special Significance in Atherosclerosis (1985) (57)
Human apolipoprotein A-I polymorphism. Identification of amino acid substitutions in three electrophoretic variants of the Münster-3 type. (1984) (56)
Plasma lipids in Turkish children: impact of puberty, socioeconomic status, and nutrition on plasma cholesterol and HDL. (2001) (55)
Turkish Population Structure and Genetic Ancestry Reveal Relatedness among Eurasian Populations (2012) (55)
Lipid transport in liver. II. Electron microscopic and biochemical studies of alterations in lipoprotein transport induced by cortisone in the rabbit. (1968) (53)
Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol. (2003) (53)
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured swine aortic smooth muscle cells by plasma lipoproteins (1975) (51)
Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E(Arg 112,Cys142). (1994) (50)
Alzheimer disease: Multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches (2009) (50)
Swine Aortic Smooth Muscle in Tissue Culture: Some Effects of Purified Swine Lipoproteins on Cell Growth and Morphology (1976) (49)
ALTERATIONS IN METABOLIC ACTIVITY OF PLASMA LIPOPROTEINS FOLLOWING SELECTIVE CHEMICAL MODIFICATION OF THE APOPROTEINS (1980) (49)
Characterization of the lipoproteins of atherosclerotic swine. (1977) (48)
Human prions and plasma lipoproteins. (2006) (47)
Apolipoprotein E genotyping using the polymerase chain reaction and allele-specific oligonucleotide probes. (1988) (47)
Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease. (2007) (46)
Accelerated clearance of low-density and high-density lipoproteins and retarded clearance of E apoprotein-containing lipoproteins from the plasma of rats after modification of lysine residues. (1979) (46)
Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates β-amyloid protein activation of complement in vitro (1997) (46)
Expression of apolipoprotein E by cultured vascular smooth muscle cells is controlled by growth state (1988) (45)
Chylomicron Metabolism in Normal, Cholesterol-fed, and Watanabe Heritable Hyperlipidemic Rabbits (1995) (44)
Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. (1996) (44)
Role of apolipoprotein E in modulating neurite outgrowth: potential effect of intracellular apolipoprotein E. (1998) (44)
Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemias⃞s⃞ The online version of this article (available at http://www.jlr.org) contains an additional four figures. Published, JLR Papers in Press, August 1, 2005. DOI 10.1194/j (2005) (43)
Uptake of Apolipoprotein E‐Containing High Density Lipoproteins by Hepatic Parenchymal Cells (1984) (43)
A unique haplotype of the apolipoprotein B-100 allele associated with familial defective apolipoprotein B-100 in a Chinese man discovered during a study of the prevalence of this disorder. (1993) (42)
Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. (2007) (42)
Hepatic lipase overexpression lowers remnant and LDL levels by a noncatalytic mechanism in LDL receptor-deficient mice. (2001) (41)
Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) (40)
Effects of a frequent apolipoprotein E isoform, ApoE4Freiburg (Leu28-->Pro), on lipoproteins and the prevalence of coronary artery disease in whites. (1999) (39)
Hypolipidemic and Hyperlipidemic Phenotypes in Transgenic Mice Expressing Human Apolipoprotein E2* (1996) (39)
Expression of human apolipoprotein B100 in transgenic mice. Editing of human apolipoprotein B100 mRNA. (1993) (38)
Isolation and characterization of apolipoprotein E. (1986) (38)
Receptor binding activity of high-density lipoproteins containing apoprotein E from abetalipoproteinemic and normal neonate plasma. (1984) (38)
Electrophoretic screening for genetic variation in apolipoprotein C-III: identification of a novel apoC-III variant, apoC-III(Asp45-->Asn), in a Turkish patient. (1994) (37)
Cholesteryl ester accumulation in mouse peritoneal macrophages induced by beta-migrating very low density lipoproteins from patients with atypical dysbetalipoproteinemia. (1983) (37)
Apolipoprotein A-V: a potential modulator of plasma triglyceride levels in Turkss⃞ (2006) (36)
Apolipoprotein ( apo ) E 4 enhances amyloid peptide production in cultured neuronal cells : ApoE structure as a potential therapeutic target (2005) (36)
Characterization of apolipoprotein E-containing lipoproteins. (1986) (36)
Polymorphisms in the hepatic lipase gene affect plasma HDL-cholesterol levels in a Turkish population[S] (2010) (36)
Functional unit of the low density lipoprotein receptor of fibroblasts: a 100,000-dalton structure with multiple binding sites. (1981) (36)
Identification of a New Structural Variant of Human Apolipoprotein E , E 2 ( Lys , 46 , Gln ) , in a Type III Hyperlipoproteinemic Subject with the E 3 / 2 Phenotype (35)
Type III hyperlipoproteinemia: a focus on lipoprotein receptor-apolipoprotein E2 interactions. (1986) (35)
Conformation of apolipoprotein E in lipoproteins. (1993) (35)
Is ϵ4 the ancestral human apoE allele? (1999) (34)
Genetic polymorphism of apolipoprotein E: a variant form of apolipoprotein E2 distinguished by sodium dodecyl sulfate--polyacrylamide gel electrophoresis. (1984) (34)
Characterization of the plasma lipoproteins and apoproteins of the Erythrocebus patas monkey. (1976) (31)
Changes induced in the lipoproteins of Yucatan miniature swine by cholesterol feeding. (1979) (30)
Structural relationship of human apolipoprotein B48 to apolipoprotein B100. (1987) (30)
Properties of lipoproteins responsible for high affinity binding to cell surface receptors of fibroblasts and smooth muscle cells. (1978) (30)
Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. (1997) (29)
Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100 (1992) (29)
The -514 polymorphism in the hepatic lipase gene (LIPC) does not influence androgen-mediated stimulation of hepatic lipase activity. (1998) (28)
Modulation of high-density lipoproteins in a population in istanbul, Turkey, with low levels of high-density lipoproteins. (2005) (28)
Familial defective apolipoprotein B100 : Low density lipoproteins with abnormal receptor binding ( hypercholesterolemia / genetic disease / atherosclerosis / lipoprotein metabolism ) (26)
Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)]. (2000) (26)
Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS Study. (2008) (25)
Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia. (1985) (25)
Tangier disease: defective recombination of a specific Tangier apolipoprotein A-I isoform (pro-apo A-i) with high density lipoproteins. (1983) (25)
Expression of the human apolipoprotein E gene in cultured mammalian cells. (1986) (24)
Canine Lipoproteins and Atherosclerosis: II. Characterization of the Plasma Lipoproteins Associated with Atherogenic and Nonatherogenic Hyperlipidemia (1974) (24)
The role of dietary fat and cholesterol in atherosclerosis and lipoprotein metabolism. (1981) (24)
Structural organization of the lipoprotein HDLc from atherosclerotic swine. Structural features relating the particle surface and core. (1978) (24)
Thrombosis in association with atherosclerosis induced by dietary perturbations in dogs. (1976) (22)
Sources of variability in genetic association studies: Insights from the analysis of hepatic lipase (LIPC) (2002) (22)
Isolation and characterization of several plasma apolipoproteins of common marmoset monkey. (1990) (21)
Incorporation of sialic acid into sialidase-treated apolipoprotein of human, very low density lipoprotein by a pork liver sialytransferase. (1974) (21)
Uptake of chylomicrons by the liver, but not by the bone marrow, is modulated by lipoprotein lipase activity. (1997) (21)
Simultaneous accumulation of Evans blue dye and albumin in the canine aortic wall. (1977) (21)
Identification of homozygosity for a human apolipoprotein A-I variant. (1986) (20)
Erratum: New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk (Nature Genetics (2010) 42 (105-116)) (2010) (20)
Atherogenic Lipoproteins Resulting from Genetic Defects of Apolipoproteins B and E (1990) (20)
Crystallization and preliminary X-ray diffraction studies on the amino-terminal (receptor-binding) domain of human apolipoprotein E3 from serum very low density lipoproteins. (1988) (19)
Apolipoprotein E: Remarkable Protein Sheds Light on Cardiovascular and Neurological Diseases. (2017) (19)
Functional domains of apolipoprotein E and apolipoprotein B. (2009) (18)
Cellular and molecular biology of lipoprotein metabolism: characterization of lipoprotein receptor-ligand interactions. (1986) (18)
Managing dyslipidemia in Turkey: suggested guidelines for a population characterized by low levels of high density lipoprotein cholesterol. (2002) (18)
Isolation and characterization of plasma lipoproteins of common marmoset monkey. Comparison of effects of control and atherogenic diets. (1990) (18)
Smoking and obesity make a bad problem worse: genetics and lifestyle affect high density lipoprotein levels in Turks. (2006) (18)
The Turkish Lipid Problem: Low Levels of High Density Lipoproteins (2002) (17)
Is epsilon4 the ancestral human apoE allele? (1999) (17)
Human apolipoprotein B: complete cDNA sequence and identification of structural domains of the protein. (1987) (17)
Comparison of the human, canine and swine E apoproteins. (1980) (17)
Isolation and characterization of an apoprotein from the d less than 1.006 lipoproteins of human and canine lymph homologous with the rat A-IV apoprotein. (1978) (15)
Reactivity of Apolipoprotein E4 and Amyloid β Peptide (2006) (15)
Role of plasma lipoproteins in cortisone-induced fat embolism. (1972) (15)
Quantitative microautoradiography of arteries: comparison of radioactivity to silver. (1980) (13)
Atherosclerosis in the Erythrocebus patas, an old world monkey. (1980) (13)
Cholesterol Feeding: Effects on Lipoprotein Structure and Metabolism (1980) (13)
Effect of arterial stretch on transmural albumin and Evan's blue dye transport. (1981) (12)
Characterization of lipoprotein receptors on rat Fu5AH hepatoma cells. (1987) (12)
Apolipoprotein E and cholesterol metabolism (1983) (12)
Aortic transmural serum protein transport: effect of concentration, time, and location. (1981) (12)
The epidemiology of hepatitis C in turkey (1994) (11)
Preparative immobiline isoelectric focusing of plasma apolipoproteins on vertical slab gels. (1985) (10)
Receptor binding activity of lipid recombinants of apolipoprotein B-100 thrombolytic fragments. (1987) (9)
Crystal Structures of the Common Apolipoprotein E Variants: Insights into Functional Mechanisms (1993) (9)
Verapamil suppresses atherosclerosis in cholesterol fed rabbits (1982) (8)
Apolipoprotein A-IGiessen (Pro143----Arg). A mutant that is defective in activating lecithin:cholesterol acyltransferase. (1984) (8)
Receptor interactions controlling lipoprotein metabolism. (1985) (8)
Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100. (1993) (7)
Apolipoprotein E: receptor binding properties. (1985) (7)
Barr body studies from the hair. (1970) (6)
The molecular basis of atherosclerosis: concepts derived from studies of lipoprotein metabolism and cell biology. (1986) (6)
Apolipoprotein E and Human Disease (1999) (6)
Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100. (1993) (6)
Apolipoprotein E: Structure, Function, and Possible Roles in Modulating Neurite Extension and Cytoskeletal Activity (1996) (6)
Δ15, 18-tetracosadienoic acid content of sphingolipids from platel and erythrocytes of animals fed diets high in saturated or polyunsaturated fats (1978) (5)
Commentary on “Perspective on a pathogenesis and treatment of Alzheimer’s disease.” Apolipoprotein E and the mitochondrial metabolic hypothesis (2006) (5)
Cholesterol-Induced Hyperlipoproteinemia and Atherosclerosis in Dogs, Swine and Monkeys: Models for Human Atherosclerosis (1980) (5)
New Findings of the Turkish Heart Study: Guiding Treatment Suggestions for Levels of Plasma Lipids and Low HDL (2002) (5)
Cholesterol esterification by the rat liver Golgi apparatus. (1974) (5)
Lipoproteins and the pathogenesis of atherosclerosis. (1989) (4)
The type of mutation in apolipoprotein E determines whether type III hyperlipoproteinemia is expressed as a dominant or recessive trait (1990) (4)
Apolipoproteins E and C-III have opposing roles in the clearance of lipoprotein remnants in transgenic mice. (1993) (4)
Familial defective apolipoprotein B100 : Enhanced binding of monoclonal antibody MB 47 to abnormal low density lipoproteins ( hypercholesterolemia / genetic disease / atherosclerosis / apolipoprotein B100 polymorphism ) (4)
Differential effects of cytosolic apolipoprotein (APO) E3 and APOE4 on neurite outgrowth and the cytoskeleton (2000) (4)
O3-03-03: Apolipoprotein E4 and its fragment impair mitochondrial dynamics in neuronal cultures (2008) (4)
Effects of diets high in saturated fat and cholesterol on the lipid composition of canine platelets (1979) (4)
4 enhances amyloid beta peptide production in cultured neuronal cells : ApoE structure as a potential therapeutic target (2005) (4)
of a New Structural Variant of Human (1983) (3)
Apolipoprotein E synthesis in neurofibrosarcoma and schwannoma cell cultures from two individuals with neurofibromatosis (1987) (3)
5. Genetic determinants of low HDL: insights from studies of the Turkish population (1999) (3)
A Preliminary Report on the Sensitivity of Plasma Lipoproteins to Low-dose Simvastatin in Nine Turkish Men (1998) (3)
Workshop Report: Laboratory–Experimental Section (1980) (3)
Apolipoprotein E4 impairs mitochondrial function and increases reactive oxygen species in neuronal cells (2009) (3)
High density lipoprotein cholesterol in coronary artery patients: is it as low as expected? (2006) (3)
Cloning and expression of the human apolipoprotein E gene. (1986) (2)
Low HDL-C in Turks: genetic/lifestyle interactions modulate plasma levels (2005) (2)
Apolipoprotein E and Alzheimer’s disease (1995) (2)
Contributions of the Glial Injury Response to the Multifactorial Pathogenesis of Alzheimer’s Disease (2000) (2)
Defective Hepatic Lipoprotein Receptor Binding of @-Very Low Density Lipoproteins from Type I11 Hyperlipoproteinemic Patients (2011) (2)
Reply to Pomara et al. and Valcour et al.: Age and the APOE ε4/ε4 genotype in HIV-1-associated dementia (2008) (2)
Apolipoprotein (apo) E modulates hepatic very low density lipoprotein (VLDL) assembly and secretion (2000) (1)
Apolipoprotein E4 targets mitochondria and the mitochondria-associated membrane complex in neuropathology, including Alzheimer's disease (2023) (1)
P2-292 Neuron-specific apoE4 proteolysis is associated with increased tau phosphorylation in the brains of transgenic mice (2004) (1)
Apolipoprotein B gene: plasma cholesterol and atherosclerosis. (1987) (1)
Receptor Interactions of Human Apolipoprotein E (1983) (1)
Incorporation of Sialic Acid into Sialidase-Treated Apolipoprotein of Humaa Very Low Density Lipoprotein by a Pork Liver (1974) (1)
Effect of cholesterol supplementation of diets of thyroidectomized dogs on the fatty acid composition of erythrocyte phospholipids and plasma phosphatidylcholine. (1980) (1)
A common transcriptional mechanism involving R-loop and RNA abasic site regulates an enhancer RNA of APOE. (2022) (1)
Lipoproteins and arterial smooth muscle cells: regulation of cellular metabolism by swine lipoproteins. (1977) (1)
RECEPTOR BINDING ACTIVITY OF VARIANTS WITH SINGLE AMINO ACID SUBSTITUTIONS* (2001) (1)
Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma HDL and IDL (1994) (1)
A transcriptional mechanism involving R-loop, m6A modification and RNA abasic sites regulates an enhancer RNA of APOE (2022) (1)
Abstract: 566 APOLIPOPROTEIN E: STRUCTURE DETERMINES FUNCTION[MDASH]FROM ATHEROSCLEROSIS TO ALZHEIMER'S DISEASE TO AIDS (2009) (1)
Cloning of the cDNA for rat and human apolipoprotein E mRNA. (1986) (1)
Nucleotide sequence and structure of the human apolipoprotein E gene , ( Alu sequences / apoE 4 genotype / 5 ' flanking region / Sl nuclease mapping / intron ) (0)
O1-03-03 APOE in degenerating neurons is produced by neurons rather than taken up from astrocytes (2004) (0)
Non-Confidential Disclosure 1 Neurotoxic Fragments of Apolipoprotein E 4 as a Biomarker for Alzheimer ’ s Disease and Other Neurodegenerative Disorders (2013) (0)
443 CONCENTRATION OF CHOLESTEROL IN DIFFERENT BODY POOLS OF MINI-PIGS FED ATHEROGENIC AND CONTROL DIETS (1978) (0)
4.C.3 Expanding roles for apolipoprotein E in health and disease (1997) (0)
Apolipoprotein E fragmentation in human brain and CSF samples is isoform and Alzheimer's disease dependent (2009) (0)
Shinya Yamanaka, M.D., Ph.D. - 2012 Nobel Prize Laureate: how his dream of a research career provides vision for the next generation of young scientists. (2013) (0)
1FS03-5 Low HDL-C: Lessons learned from the Turkish Heart study (2003) (0)
2. Characterization of the Plasma Lipoproteins Associated with Atherogenic and Nonatherogenic Hyperlipidemia (2009) (0)
EFFECTS OF DIET-INDUCED ALTERATION AND SELECTIVE CHEMICAL MODIFICATION ON LIPOPROTEIN METABOLISM (1981) (0)
Heparin-Manganese Precipitability of Canine Lipoproteins as Correlated with Binding to the Cell Surface Receptors on Fibroblasts (1977) (0)
Quantitative proteomic analysis reveals apoE4-dependent phosphorylation of the actin-regulating protein VASP (2022) (0)
Small molecules abolish detrimental effects of apolipoprotein (apo) E4 in vitro by inhibiting domain interaction and correcting structure (2011) (0)
Roleofapolipoprotein E inthelipolytic conversion ofa-very low density lipoproteins tolowdensity lipoproteins in (1984) (0)
Receptor-Mediated Regulation of Cholesterol Metabolism (1987) (0)
Low HDL-C: lessons learned from the Turkish Heart Study (2004) (0)
CLINICAL CASE SEMINAR Familial Splenomegaly: Macrophage Hypercatabolism of Lipoproteins Associated with Apolipoprotein E Mutation (Apolipoprotein E (D149 Leu)) (2000) (0)
Role of apolipoprotein E in the lipolytic conversion of avery low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia ( lipoprotein metabolism / lipoprotein lipase ) (0)
Hyperlipidemia by Stimulating Hepatic VLDL Production and Impairing VLDL Lipolysis Overexpression of Apolipoprotein E 3 in Transgenic Rabbits Causes Combined (1999) (0)
Regulation of Rat Liver Apolipoprotein E mRNA and Cloning of Its cDNA (1983) (0)
Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders (2016) (0)
O4-01-05 Profile and regulation of APOE expression in central nervous system in mice with targeting of green fluorescent protein gene to the APOE locus (2006) (0)
Advancing Alzheimer's Diagnosis, Treatment and Care: Recommendations from the Ware Invitational Summit (2013) (0)
Workshop abstractSecretion/capture of apolipoprotein E: role in chylomicron remnant uptake (1994) (0)
The Cytoskeleton and the Paranode (2006) (0)
Pathology: plasma cholesterol levels determined by lipoprotein interactions with cell surface receptors. (1986) (0)
Contents (2007) (0)
Apolipoprotein E4-induced mitochondrial dysfunction depends on its structure and can be rescued by a structure corrector (2009) (0)
Neuroimaging analysis of human apolipoprotein E targeted replacement mice that overexpress amyloid precursor protein (2009) (0)
Immunochemical Identification of Very Low Density Serum Lipoproteins in Golgi Apparatus from Rat Liver (1967) (0)
FuSAH hepatoma cells (1987) (0)
Characterization of lipoproteins in human and canine cerebrospinal fluid (CSF) (1986) (0)
Δ15,18-Tetracosadienoic acid content of sphingolipids from platelets and erythrocytes of animals fed diets high in saturated or polyunsaturated fats (2006) (0)
Going beneath the fold (2006) (0)
Lipoprotein Receptors and Their Ligands: Structure and Function of Apoproteins E and B (1987) (0)
Reviews Low Levels of High-Density Lipoproteins in the Turkish Population: A Risk Factor for Coronary Heart Disease (1999) (0)
The J. David Gladstone Institutes (1997) (0)
Identification of a tryptic fragment of apo lipo protein b implicated in low density lipo protein binding to apo lipo protein b e receptors (1983) (0)
Divergent Metabolism of Apolipoproteins E3 and E4 by Cells (1998) (0)
Mutations of apolipoprotein AI can affect cofactor function for cholesteryl ester formation by lecithin: cholesterol acyltransferase. (1984) (0)
Apolipoprotein E as a therapeutic target for Alzheimer's disease (2009) (0)
Apolipoprotein E4 expression inhibits neurite outgrowth from neuroblastoma cells (1995) (0)
Cellular and Molecular Biology of Apolipoproteins: Receptor-Mediated Regulation of Cholesterol Metabolism (1987) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert W. Mahley?

Robert W. Mahley is affiliated with the following schools: